VIP enhances phagocytosis of fibrillar beta-amyloid by microglia and attenuates amyloid deposition in the brain of APP/PS1 mice

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Song, Min ^a   Xiong, Jia xiang ^a   Wang, Yan yan ^a   Tang, Jun ^a   Zhang, Bo ^a   Bai, Yun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; GAMMA INTERFERON; NITRIC OXIDE; PROTEIN KINASE C; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE; AMYLOID;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CELL ACTIVATION; CELL ACTIVITY; CELL METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE TARGETING; HIPPOCAMPUS; HORMONE RELEASE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MICROGLIA; MOUSE; NEUROMODULATION; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; CELL CULTURE; CELL LINE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NICK END LABELING; PHYSIOLOGY; TRANSGENIC MOUSE;

ADENOVIRIDAE; ANIMALIA; MUS; MUS MUSCULUS;

AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CELL LINE; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, TRANSGENIC; MICROGLIA; MICROSCOPY, FLUORESCENCE; NITRIC OXIDE; PHAGOCYTOSIS; TUMOR NECROSIS FACTOR-ALPHA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84856668816     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029790     Document Type: Article

References (39)

1. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
2. Henry W, Querfurth FL, (2010) Alzheimer's disease. N Engl J Med 362: 329-44.
3. Wyss-Coray T, (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12: 1005-1015.
4. Rivest S, (2009) Regulation of innate immune responses in the brain. Nat Rev Immunol 9: 429-439.
5. Mandrekar-Colucci S, Landreth GE, (2010) Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets 9: 156-167.
6. Monsonego A, Weiner HL, (2003) Immunotherapeutic approaches to Alzheimer's disease. Science 302: 834-8.
7. Reinke E, Fabry Z, (2006) Breaking or making immunological privilege in the central nervous system: the regulation of immunity by neuropeptides. Immunol Lett 104: 102-9.
8. Liu J, Chen M, Wang X, (2000) Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology 101: 61-7.
9. Wu R, Zhou M, Wang P, (2003) Adrenomedullin and adrenomedullin binding protein-1 downregulate TNF-alpha in macrophage cell line and rat Kupffer cells. Regul Pept 112: 19-26.
10. Bedoui S, Miyake S, Lin Y, Miyamoto K, Oki S, et al. (2003) Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J Immunol 171: 3451-8.
11. Muhvic D, Radosevic-Stasic B, Pugel E, Rukavina D, Sepcic J, et al. (1992) Modulation of experimental allergic encephalomyelitis by somatostatin. Ann N Y Acad Sci 650: 170-8.
12. Delgado M, Pozo D, Ganea D, (2004) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56: 249-90.
13. Gonzalez-Rey E, Delgado M, (2005) Role of vasoactive intestinal peptide in inflammation and autoimmunity. Curr Opin Investig Drugs 6: 1116-23.
14. Loren I, Emson PC, Fahrenkrug J, Bjorklund A, Alumets J, et al. (1979) Distribution of vasoactive intestinal polypeptide in the rat and mouse brain. Neuroscience 4: 1953-76.
15. Farmery SM, Owen F, Poulter M, Crow TJ, (1984) Characterisation and distribution of vasoactive intestinal polypeptide binding sites in human brain. Neuropharmacology 23: 101-4.
16. Joo KM, Chung YH, Kim MK, Nam RH, Lee BL, et al. (2004) Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. J Comp Neurol 476: 388-413.
17. Delgado M, Jonakait GM, Ganea D, (2002) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia 39: 148-61.
18. Martinez C, Abad C, Delgado M, Arranz A, Juarranz MG, et al. (2002) Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A 99: 1053-8.
19. Grimm MC, Newman R, Hassim Z, Cuan N, Connor SJ, et al. (2003) Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J Immunol 171: 4990-4.
20. Glowa JR, Panlilio LV, Brenneman DE, Gozes I, Fridkin M, et al. (1992) Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res 570: 49-53.
21. Gozes I, Glowa J, Brenneman DE, McCune SK, Lee E, et al. (1993) Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. J Mol Neurosci 4: 185-193.
22. Arai H, Moroji T, Kosaka K, (1984) Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer-type dementia. Neurosci Lett 52: 73-8.
23. Zhou JN, Hofman MA, Swaab DF, (1995) VIP neurons in the human SCN in relation to sex, age, and Alzheimer's disease. Neurobiol Aging 16: 571-6.
24. Delgado M, Varela N, Gonzalez-Rey E, (2008) Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia 56: 1091-1103.
25. De la Fuente M, Delgado M, del Rio M, Martinez C, Hernanz A, et al. (1993) Stimulation by vasoactive intestinal peptide (VIP) of phagocytic function in rat macrophages. Protein kinase C involvement. Regul Pept 48: 345-53.
26. Tan J, Town T, Paris D, Mori T, Suo Z, et al. (1999) Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286: 2352-5.
27. Krishnadas A, Onyuksel H, Rubinstein I, (2003) Interactions of VIP, secretin and PACAP(1-38) with phospholipids: a biological paradox revisited. Curr Pharm Des 9: 1005-12.
28. Lodde BM, Delporte C, Goldsmith CM, Tak PP, Baum BJ, (2004) A recombinant adenoviral vector encoding functional vasoactive intestinal peptide. Biochem Biophys Res Commun 319: 189-92.
29. Reinke E, Fabry Z, (2006) Breaking or making immunological privilege in the central nervous system: the regulation of immunity by neuropeptides. Immunol Lett 104: 102-9.
30. El Zein N, Badran B, Sariban E, (2008) VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1 J. Leukoc Biol 83: 972-981.
31. Choucair-Jaafara N, Laporteb V, Levya R, Poindrona P, Lombarda Y, et al. (2011) CD11b can enhance microglia uptake of artificial amyloid deposits. Fundam Clin Pharmacol 25: 115-22.
32. Heneka MT, Loschmann PA, Gleichmann M, Weller M, Schulz JB, et al. (1998) Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. J Neurochem 71: 88-94.
33. Combs CK, Karlo JC, Kao SC, Landreth GE, (2001) beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21: 1179-88.
34. Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, et al. (1998) Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 18: 2161-73.
35. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D, (2001) Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging 22: 1007-12.
36. Delgado M, Ganea D, (2003) Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 17: 944-6.
37. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, et al. (1996) Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci U S A 93: 427-32.
38. Zhu Y, Hou H, Nikolic WV, Ehrhart J, Rrapo E, et al. (2008) CD45RB Is a Novel Molecular Therapeutic Target to Inhibit Ab Peptide-Induced Microglial MAPK Activation. PLoS ONE 3 (5): e2135.
39. He TC, Zhou Sb, Da Costa LT, Jian Y, Kinzler KW, et al. (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95: 2509-2514.